Clinical impact of high-throughput gene expression studies in lung cancer.
Clinical impact of high-throughput gene expression studies in lung cancer.
复制标题
DOI：
10.1097/jto.0b013e31819151f8
复制
发表时间：
2009-01
期刊：
影响因子：
--
通讯作者：
Lenburg ME
中科院分区：
文献类型：
--
作者：
Beane J;Spira A;Lenburg ME
肺癌是美国和世界癌症死亡的主要原因。高死亡率的部分原因是缺乏有效的早期检测工具以及无法识别可从辅助化疗或靶向治疗中受益的患者亚群。用于测量基因表达的高通量全基因组技术（例如微阵列）的发展有可能通过改善诊断、预后和治疗来影响肺癌患者的死亡率。这篇综述将重点介绍最近使用高通量基因表达技术的研究，这些研究对肺癌产生了临床相关的见解。希望作为这项工作的一部分开发的诊断和预后生物标志物将很快为广泛的临床应用做好准备，并将对疑似肺癌患者的评估产生巨大影响，从而产生有效的个性化治疗方案。
Lung cancer is the leading cause of cancer death in the US and the world. The high mortality rate results, in part, from the lack of effective tools for early detection and the inability to identify subsets of patients who would benefit from adjuvant chemotherapy or targeted therapies. The development of high-throughput genome-wide technologies for measuring gene expression, such as microarrays, have the potential to impact the mortality rate of lung cancer patients by improving diagnosis, prognosis, and treatment. This review will highlight recent studies using high-throughput gene expression technologies that have led to clinically relevant insights into lung cancer. The hope is that diagnostic and prognostic biomarkers that have been developed as part of this work will soon be ready for wide-spread clinical application and will have a dramatic impact on the evaluation of patients with suspect lung cancer, leading to effective personalized treatment regimens.